Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Stake Lifted by Arkadios Wealth Advisors

Key Points

• Arkadios Wealth Advisors increased its holdings in Jazz Pharmaceuticals by 118.7%, owning 12,710 shares valued at approximately $1.58 million at the end of the last quarter.
• The company reported a missed earnings estimate of $1.68 EPS for the quarter, falling short of analysts' expectations of $4.65, with a revenue of $897.84 million.
• Jazz Pharmaceuticals has a market capitalization of $6.99 billion and a consensus rating of "Moderate Buy" with a target price of $181.64 from analysts.

Arkadios Wealth Advisors raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 118.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,710 shares of the specialty pharmaceutical company's stock after acquiring an additional 6,899 shares during the quarter. Arkadios Wealth Advisors' holdings in Jazz Pharmaceuticals were worth $1,578,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Hurley Capital LLC purchased a new stake in Jazz Pharmaceuticals during the first quarter worth $25,000. Quadrant Capital Group LLC boosted its position in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after purchasing an additional 101 shares in the last quarter. Elequin Capital LP raised its holdings in shares of Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 183 shares during the last quarter. Parallel Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 85.6% in the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock worth $32,000 after acquiring an additional 119 shares during the last quarter. Finally, Spire Wealth Management raised its holdings in shares of Jazz Pharmaceuticals by 137.6% in the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock worth $35,000 after acquiring an additional 161 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Seamus Mulligan purchased 100,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 9th. The stock was purchased at an average price of $98.26 per share, with a total value of $9,826,000.00. Following the completion of the acquisition, the director owned 100,000 shares of the company's stock, valued at approximately $9,826,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the transaction, the chief executive officer directly owned 436,973 shares of the company's stock, valued at $47,031,403.99. This represents a 0.23% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Stock Up 0.5%

Shares of JAZZ stock traded up $0.58 during trading hours on Monday, reaching $116.10. The company had a trading volume of 597,795 shares, compared to its average volume of 612,609. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.97 and a current ratio of 3.38. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06. The company has a market capitalization of $7.03 billion, a P/E ratio of 15.48, a price-to-earnings-growth ratio of 5.56 and a beta of 0.34. The stock's fifty day simple moving average is $111.08 and its 200 day simple moving average is $117.78.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The company had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. Jazz Pharmaceuticals's quarterly revenue was down .5% compared to the same quarter last year. During the same quarter last year, the business posted $2.68 EPS. As a group, sell-side analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Royal Bank Of Canada cut their price target on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Needham & Company LLC reiterated a "buy" rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, June 11th. Morgan Stanley dropped their target price on Jazz Pharmaceuticals from $166.00 to $165.00 and set an "overweight" rating for the company in a research note on Tuesday, July 22nd. Piper Sandler reiterated an "overweight" rating and issued a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Finally, Wall Street Zen lowered Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $181.64.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.